CCCC
C4 Therapeutics, Inc.2.2600
-0.1700-7%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
219.03MP/E (TTM)
-Basic EPS (TTM)
-1.67Dividend Yield
0%Recent Filings
10-K
FY2025 results
C4 Therapeutics posted a stable $105.0M net loss for FY2025 ended December 31, matching 2024's $105.3M amid clinical investments, with collaboration revenue holding at $35.9M (flat y/y) from Merck KGaA, Roche, and others offsetting Biogen's wind-down. Q4 momentum built as Phase 2 MOMENTUM trial for cemsidomide + dexamethasone dosed its first patient in February 2026, while Phase 1b with Pfizer-supplied elranatamab advanced dose determination. Cash swelled to $297.1M post-$117M October offering, funding operations into 2028. R&D dipped to $104.2M on trial completions. Clinical trials may fail to show adequate safety-efficacy.
8-K
Cemsidomide Phase 2 trial dosed
C4 Therapeutics reported Q4 and full-year 2025 results, dosing the first patient in the Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone for fourth-line multiple myeloma, targeting accelerated approval with ~100 patients by Q1 2027. Cash hit $297.1 million, funding operations through 2028 after a $125 million offering. R&D expenses dropped to $104.2 million yearly. Progress accelerates.
8-K
Cemsidomide milestones to 2028
C4 Therapeutics issued a press release on January 14, 2026, outlining milestones through 2028, spotlighting cemsidomide's Phase 2 MOMENTUM trial initiation in Q1 2026 at 100 µg dose and Phase 1b combo with elranatamab in Q2 2026 for relapsed/refractory multiple myeloma. Phase 1 data showed 53% ORR at top dose in pretreated patients. Cash runway extends to end of 2028. Trials advance swiftly.
8-K
Raised $125M, strong MM data
C4 Therapeutics raised $125M in gross proceeds from an October equity offering, extending cash runway to end-2028 past key cemsidomide milestones. Phase 1 multiple myeloma data showed 53% overall response rate at 100µg dose with dexamethasone, plus Pfizer collaboration for elranatamab combo. Q3 revenue fell to $11.2M while net loss widened to $32.2M. MOMENTUM Phase 2 trial starts Q1 2026.
10-Q
Q3 FY2025 results
C4 Therapeutics posted Q3 revenue of $11.2M from collaborations, down 27% y/y from $15.4M yet up sequentially (derived), as Biogen milestones slowed while MKDG, Roche, and a full Merck unwind added $3.4M, $2.0M, and $3.8M respectively. R&D eased 18% y/y to $26.0M on lower clinical and preclinical costs, G&A dropped 24% to $8.9M from reduced stock comp, but a $10.7M long-lived asset impairment—tied to a new sublease ending Jan 2029—drove operating loss wider to $34.4M (vs $28.2M y/y) and net loss to $32.2M or $(0.44) per share on 72.6M diluted shares. Cash and marketable securities stood at $199.8M, bolstered by $7.5M ATM proceeds; Oct 2025 offering added $117M net (up to $342M if warrants exercised). Solid runway, but clinical-stage cash burn persists.
IPO
Employees
Sector
Industry
CAMP
CAMP4 THERAPEUTICS CORPORATION
7.01+0.26
CASI
CASI Pharmaceuticals, Inc.
0.88+0.01
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
CUE
Cue Biopharma, Inc.
0.41-0.05
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
ORIC
Oric Pharmaceuticals, Inc.
9.12-0.11
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05